Latest news with #autoimmune
Yahoo
5 days ago
- Business
- Yahoo
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
Dr. Zuraw led clinical development of telitacicept across MG, Sjögren's, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio's new development focus and execution of late-stage programs CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately. Dr. Zuraw joins Vor Bio with over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory, and immunologic diseases. Most recently, she served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases at RemeGen Co., Ltd., where she was one of the key leaders of successful development and execution of clinical trials for telitacicept across four key indications—systemic lupus erythematosus (SLE), Sjögren's syndrome, myasthenia gravis (MG), and rheumatoid arthritis (RA)—culminating in regulatory approvals in China for the treatment of SLE, generalized MG and RA. At RemeGen, Dr. Zuraw built and led a cross-functional global team that managed all aspects of telitacicept development, including clinical trial design, regulatory strategy, site engagement, and execution. She played a central role in regulatory interactions with the U.S. Food & Drug Administration, European Medicines Agency, and China's Center for Drug Evaluation, achieving Fast Track, Breakthrough Therapy, and Orphan Drug designations for telitacicept across multiple indications. 'We are delighted to welcome Qing to Vor Bio at a critical time for the company,' said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. 'Her deep and diverse clinical development expertise across autoimmune and immunological diseases and with telitacicept will be invaluable as we execute on our late-stage programs. Qing's ability to lead high-performing clinical organizations will be instrumental as we drive forward our global development programs, particularly in the U.S.' Dr. Zuraw has also previously held senior leadership roles at Janssen Research & Development, Teva Pharmaceutical Industries Ltd., Akebia Therapeutics, Inc., Biogen Inc., and Covance, Inc., where she led global clinical development programs across rheumatology, nephrology, respiratory, and immunology. She played a key role in the U.S. FDA approval of Guselkumab for psoriatic arthritis and contributed to multiple NDA and BLA submissions across therapeutic areas. Throughout her career, she has built and led high-performing teams to execute complex trials from early development through post-marketing. 'Vor Bio is uniquely positioned to become a leader in autoimmune therapeutics,' said Dr. Zuraw. 'Having been intimately involved in the development of telitacicept in China from early clinical stages through to multiple approvals, I'm thrilled to join the talented team at Vor Bio to bring telitacicept to patients globally.' About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words 'aim,' 'anticipate,' 'can,' 'continue,' 'could,' 'design,' 'enable,' 'expect,' 'initiate,' 'intend,' 'may,' 'on-track,' 'ongoing,' 'plan,' 'potential,' 'should,' 'target,' 'update,' 'will,' 'would,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio's statements regarding Vor Bio's development plans for telitacicept, its ability to change the treatment landscape for patients with autoimmune conditions and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption 'Risk Factors' included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. Media & Investor Contacts:Sarah Spencer+1 857-242-6076investors@ Carl Mauchinvestors@ in to access your portfolio
Yahoo
6 days ago
- Business
- Yahoo
GeNeuro SA Announces the Liquidation of Its French Subsidiary GeNeuro Innovation SAS
GENEVA, July 16, 2025--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Lyon Economic Activities Court has pronounced on July 15, 2025, the liquidation of GeNeuro Innovation SAS, the sole subsidiary of GeNeuro SA. This decision follows the opening on June 11, 2025, of receivership proceedings for GeNeuro Innovation SAS. The Court appointed SELARL MJ-Synergie as liquidator. This is part of the restructuring process of the GeNeuro Group, which announced on May 27 that it had obtained a definitive debt-restructuring moratorium until September 28, 2025, in Switzerland for its parent company, GeNeuro SA, a moratorium which is not affected by the receivership of its subsidiary. About GeNeuro GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. GeNeuro is based in Geneva, Switzerland. For more information, visit: X YouTube LinkedIn Disclaimer This press release contains certain forward - looking statements and estimates concerning GeNeuro's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company's control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law. View source version on Contacts GeNeuro Jesús Martin-GarciaChairman and CEOinvestors@
Yahoo
14-07-2025
- Health
- Yahoo
Patient left to 'waste away' on wrong hospital ward
An engineer says he was "left to waste away" after he developed a rare medical condition that has left him in hospital for more than 200 days. Kevin Heard, 56, said he developed Guillain-Barré syndrome, an autoimmune condition, after he carried on working despite a bad case of flu. He now uses a wheelchair and is currently unable to write. Mr Heard, from Sutton Benger in Wiltshire, claimed he was placed on the wrong ward, which hindered his recovery, but hopes to raise awareness of the illness which affects 1,300 people in the UK every year. Luisa Goddard, chief nurse at Great Western Hospital, said she was "sorry that Mr Heard's experience did not reflect the standards we strive to uphold". Mr Heard, who was previously healthy, said that his recovery had not been aided by being placed on a respiratory ward, when he should have been on a neurology ward, which prevented him from receiving necessary physiotherapy. He said: "There is another side to my battle with my recovery that is to do with the NHS and how I've been treated. I was put on an incorrect ward and left to waste away." Ms Goddard said that when their neurology beds are full, "patients may need to be cared for in other parts of the hospital". She said: "Following Mr Heard's feedback, we have taken steps to review and improve our approach to patients who need enhanced care and specialist support for complex conditions such as Guillain-Barre syndrome. "We are also placing a renewed focus on preventing deconditioning and ensuring patients remain active and independent during their hospital stay through additional training, regular monitoring and meaningful activities for patients." Mr Heard now hopes to be able to leave Chippenham Community Hospital by the end of August. He said his illness began with a persistent cold and cough last summer. "I then got the flu, but I carried on working," he said. "By the middle of November, my left leg was starting to lose power, and my left hand side of my body had started to give problems, so I thought I was having a stroke. "I admitted myself into Great Western Hospital [in Swindon]. Eighteen hours and 32 doctors later, I was diagnosed with Guillain-Barré syndrome." At one point, Mr Heard was put in an induced coma for two days, to give his lungs a rest and received five rounds of plasma infusions. Although his symptoms are now improving, Mr Heard said it had been a "long and slow process" to get where he is today. He still struggles to feed himself and has had to relearn how to walk. "Every day is a learning day to overcome the problems with this debilitating illness," he said. "All of my nerves are functioning. They've all got their coating back. "I'm now standing for at least a minute (at a time), but I'd never have thought this time last year that I'd be learning to walk for the second time in my life." He hopes to be able to walk out of the hospital with a frame by the end of August and to be able to return to work, but not "for at least a year" to allow his body to "build fatigue resilience". He does not know if he will ever fully recover – and advises those who feel unusually ill to seek medical help. The decision not to rest while feeling ill, he said, may have contributed to his need to spend months in hospital. "Don't be a martyr. Have some rest, because not all of us are very good at doing that". It is a very rare and serious condition which affects the nerves. It mainly affects the feet, hands and limbs, causing problems such as numbness, weakness and pain. The symptoms include numbness and pins and needles starting in the feet and hands before spreading to the arms and legs. You can also have muscle weakness, pain and problems with balance and co-ordination. In severe cases, you may have difficulty moving, walking, breathing and swallowing. About one in 20 cases is fatal. It can be triggered by an infection, in extremely rare cases a vaccination, surgery, a medical procedure or an injury Some people will not make a full recovery and are left with long-term problems such as being unable to walk without assistance, weakness in the arms, legs or face, numbness, pain or a tingling or burning sensation, balance and co-ordination problems and extreme tiredness. Source: NHS UK Follow BBC Wiltshire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630. 'Fragile' girl's life transformed by 'loving' hospice Disabled woman denied wheelchair over 'criteria' Great Western Hospital
BBC News
14-07-2025
- Health
- BBC News
Patient says he was left to 'waste away' on wrong hospital ward
An engineer says he was "left to waste away" after he developed a rare medical condition that has left him in hospital for more than 200 Heard, 56, said he developed Guillain-Barré syndrome, an autoimmune condition, after he carried on working despite a bad case of flu. He now uses a wheelchair and is currently unable to Heard, from Sutton Benger in Wiltshire, claimed he was placed on the wrong ward, which hindered his recovery, but hopes to raise awareness of the illness which affects 1,300 people in the UK every Goddard, chief nurse at Great Western Hospital, said she was "sorry that Mr Heard's experience did not reflect the standards we strive to uphold". Mr Heard, who was previously healthy, said that his recovery had not been aided by being placed on a respiratory ward, when he should have been on a neurology ward, which prevented him from receiving necessary said: "There is another side to my battle with my recovery that is to do with the NHS and how I've been treated. I was put on an incorrect ward and left to waste away."Ms Goddard said that when their neurology beds are full, "patients may need to be cared for in other parts of the hospital".She said: "Following Mr Heard's feedback, we have taken steps to review and improve our approach to patients who need enhanced care and specialist support for complex conditions such as Guillain-Barre syndrome."We are also placing a renewed focus on preventing deconditioning and ensuring patients remain active and independent during their hospital stay through additional training, regular monitoring and meaningful activities for patients."Mr Heard now hopes to be able to leave Chippenham Community Hospital by the end of said his illness began with a persistent cold and cough last summer. "I then got the flu, but I carried on working," he said."By the middle of November, my left leg was starting to lose power, and my left hand side of my body had started to give problems, so I thought I was having a stroke."I admitted myself into Great Western Hospital [in Swindon]. Eighteen hours and 32 doctors later, I was diagnosed with Guillain-Barré syndrome." At one point, Mr Heard was put in an induced coma for two days, to give his lungs a rest and received five rounds of plasma his symptoms are now improving, Mr Heard said it had been a "long and slow process" to get where he is still struggles to feed himself and has had to relearn how to walk."Every day is a learning day to overcome the problems with this debilitating illness," he said."All of my nerves are functioning. They've all got their coating back."I'm now standing for at least a minute (at a time), but I'd never have thought this time last year that I'd be learning to walk for the second time in my life."He hopes to be able to walk out of the hospital with a frame by the end of August and to be able to return to work, but not "for at least a year" to allow his body to "build fatigue resilience".He does not know if he will ever fully recover – and advises those who feel unusually ill to seek medical decision not to rest while feeling ill, he said, may have contributed to his need to spend months in hospital."Don't be a martyr. Have some rest, because not all of us are very good at doing that". What is Guillain-Barre syndrome? It is a very rare and serious condition which affects the mainly affects the feet, hands and limbs, causing problems such as numbness, weakness and symptoms include numbness and pins and needles starting in the feet and hands before spreading to the arms and legs. You can also have muscle weakness, pain and problems with balance and co-ordination. In severe cases, you may have difficulty moving, walking, breathing and one in 20 cases is can be triggered by an infection, in extremely rare cases a vaccination, surgery, a medical procedure or an injurySome people will not make a full recovery and are left with long-term problems such as being unable to walk without assistance, weakness in the arms, legs or face, numbness, pain or a tingling or burning sensation, balance and co-ordination problems and extreme NHS UK
Medscape
11-07-2025
- Health
- Medscape
Endocrine Society Statement Outlines Knowledge Gaps in T1D
A new Endocrine Society scientific statement outlines 'challenges and opportunities' in understanding the pathogenesis of type 1 diabetes (T1D), with some clinical takeaways regarding the heterogeneity of the condition and the need for increased screening for preclinical disease. The statement was published on July 9, 2025 in The Journal of Clinical Endocrinology & Metabolism and will be presented July 14, 2025 at ENDO 2025: The Endocrine Society Annual Meeting. It summarizes what is known and what is still to be learned about the autoimmune process leading to pancreatic beta cell destruction, the genetics and immunology involved, and the heterogeneity of the patient population, including the large but often unrecognized group who develop the condition in adulthood. The statement also reviews recent advances in the early identification of preclinical T1D and the emergence of stategies to delay onset including teplizumab (Tzield), which is already on the market. 'It's such an incredibly exciting time in type 1 diabetes now, on so many different levels, that the Endocrine Society felt that it was a good time to talk about the pathogenesis,' writing committee member Alvin C. Powers, MD, professor of medicine and director of the Diabetes Center at Vanderbilt University, Nashville, Tennessee, told Medscape Medical News . The heterogeneity of T1D is important to recognize clinically, particularly the high incidence of new-onset T1D in adults despite its former characterization as a 'juvenile' disease. 'We now think that maybe a third of people who have type 1 develop it over the age of 30, maybe even 40%,' Powers noted. But, often in adulthood the beta cell destruction is slower and individuals may not require insulin treatment right away, leading to a potential misdiagnosis of type 2 diabetes. Other sources of heterogeneity outlined in the document include the severity of hyperglycemia at onset, the intensity of islet-directed autoimmunity, contributors such as obesity and insulin resistance, and rate/degree of beta cell loss. Asked to comment, endocrinologist M. Sue Kirkman, MD, professor of medicine at the University of North Carolina at Chapel Hill, told Medscape Medical News, 'The statement provides clear descriptions of what we do and especially still don't know about the pathogenesis of type 1 diabetes. The knowledge gaps and suggested future efforts may be of the most interest to more basic researchers, but as an adult endocrinologist, I appreciated the emphasis on the need to understand adult-onset type 1 diabetes more.' The document also reviews the three stages of T1D: In stage 1, the individual has two or more autoantibodies directed against glutamic acid decarboxylase, insulin, insulinoma antigen-2 and/or zinc transporter 8, but glycemia is still normal. In stage 2, there are multiple autoantibodies and dysglycemia, but not yet to the point of insulin requirement. Stage 3 is clinical T1D. Powers noted, 'there is great interest in trying to understand the pathogenesis and screen individuals who are at high risk for developing type 1 diabetes, because there now is one disease-modifying therapy out there. In order to get that, people are going to have to be identified as having one of these autoantibodies.' When Is Preventive Screening Warranted? General population screening isn't yet universal, but 'certainly people who have a family member with type 1 diabetes should be screened for this, even though we know that 75% of people who have type 1 diabetes don't have anybody else in their family with it. But if you have someone with type 1 diabetes in your family, you are at higher risk and should be screened and if positive, should be referred to a center of excellence that is involved in administering [teplizumab],' Powers recommended, adding that it does have side effects and is fairly expensive. However, he also noted, the value of such screening in adults and in relatives of those with adult-onset T1D is unclear. 'These antibodies are great at predicting whether a 12-year-old sibling of someone who has type 1 diabetes is going to get diabetes but what we don't know is about a 52-year-old who develops what we think is type 1 diabetes, when did they start having autoantibodies, in their teenage years, or did those antibodies form when they were in their 40's? We don't have a clue about that.' Indeed, Kirkman pointed out, 'the issue of screening for T1D risk in adults is murky, since these people have avoided childhood-onset disease so the more well-known risk factors may not be as predictive. It's also important to stress that a lot of what we know is based on children and younger people of White European descent, whereas there are many people of other races/ethnicities that develop type 1 diabetes.' Powers is involved in a study called RADIANT exploring the overall heterogeneity of diabetes and currently enrolling people who don't fit the typical pictures of type 1 or type 2 diabetes. Powers and Kirkman had no disclosures.
